18 December 2024NewsAmericasRajiv Nayar, President, HTD Biosystems | Chuck Sholtz, Vice President, Intellectual Property, Nutcracker Therapeutics | Benjamin Pelletier, Partner, Haynes & Boone

WATCH: What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies?

Speakers from HTD Biosystems, Nutcracker Therapeutics, and Haynes & Boone examine the evolving patent landscape for biologics, biosimilars, and bispecific antibodies, sharing practical strategies and jurisdiction-specific insights.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Fed Circ: Generic doesn’t infringe Metacel MS drug

WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025

Strategic IP protection for biotech-related GenAI

South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug

Patent litigator with biotech and medical device background joins Sterlington

Resilience and the power of brands: Elisabeth Stewart Bradley on 9/11, inclusion and the INTA presidency

Fenwick establishes new Boston office with trio of IP partners from Cooley

How pharma should prep for the six-bill avalanche from Congress

WATCH: What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies?

Editor's picks

Editor's picks

More features